COX.PA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 apr 2023 @ 17:35):

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health...

Stats
Dagens volum	246 141
Gjennomsnittsvolum	196 980
Markedsverdi	29.04M
EPS	€0 ( 2024-04-17 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.456
ATR14	€0.0560 (9.49%)

Volum Korrelasjon

Lang: -0.11 (neutral)

Kort: -0.95 (very strong negative)

Signal:(45.399) Neutral

Nicox SA Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Nicox SA Korrelasjon - Valuta/Råvare

0.39
( neutral )

-0.52
( weak negative )

0.00
( neutral )

0.07
( neutral )

0.80
( moderate )

-0.46
( neutral )

Nicox SA Økonomi

Annual	2022
Omsetning:	€5.24M
Bruttogevinst:	€3.27M (62.40 %)
EPS:	€0

FY	2022
Omsetning:	€5.24M
Bruttogevinst:	€3.27M (62.40 %)
EPS:	€0

FY	2021
Omsetning:	€8.58M
Bruttogevinst:	€7.23M (84.27 %)
EPS:	€-1.170

FY	2020
Omsetning:	€14.42M
Bruttogevinst:	€12.91M (89.49 %)
EPS:	€-0.540

Financial Reports:

No articles found.

Nicox SA

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.